Weight bearing as a measure of disease progression and efficacy of anti-inflammatory compounds in a model of monosodium iodoacetate-induced osteoarthritis  by Bove, S.E et al.
Weight bearing as a measure of disease progression and efficacy of
anti-inflammatory compounds in a model of monosodium
iodoacetate-induced osteoarthritis
S. E. Bove M.S., S. L. Calcaterra M.S., R. M. Brooker B.S., C. M. Huber B.S.,
R. E. Guzman D.V.M., Ph.D., P. L. Juneau M.S., D. J. Schrier Ph.D. and K. S. Kilgore Ph.D.*
Department of Inflammation Pharmacology, Pfizer Global Research and Development,
Ann Arbor Laboratories, Ann Arbor, MI 48105, USA
Summary
Objective: To describe an in vivo model in the rat in which change in weight distribution is used as a measure of disease progression and
efficacy of acetaminophen and two nonsteroidal anti-inflammatory drugs (NSAIDs) in a model of monosodium iodoacetate (MIA)-induced
osteoarthritis (OA).
Methods: Intra-articular injections of MIA and saline were administered to male Wistar rats (175–200 g) into the right and left knee joints,
respectively. Changes in hind paw weight distribution between the right (osteoarthritic) and left (contralateral control) limbs were utilized as
an index of joint discomfort. Acetaminophen and two archetypal, orally administered NSAIDs, naproxen and rofecoxib, were examined for
their ability to decrease MIA-induced change in weight distribution.
Results: A concentration-dependent increase in change in hind paw weight distribution was noted after intra-articular injection of MIA. Both
naproxen and rofecoxib demonstrated the capacity to significantly (P<0.05) decrease hind paw weight distribution in a dose-dependent
fashion, indicating that the change in weight distribution associated with MIA injection is susceptible to pharmacological intervention.
Conclusion: The determination of differences in hind paw weight distribution in the rat MIA model of OA is a technically straightforward,
reproducible method that is predictive of the effects of anti-inflammatory and analgesic agents. This system may be useful for the discovery
of novel pharmacologic agents in human OA.
© 2003 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Introduction
Osteoarthritis (OA) is the most common form of joint
disease with over one-half of all people older than 65 years
of age demonstrating radiographic changes of OA in the
knees1. OA is primarily noted in the weight-bearing joints
(i.e., knees, hips) and involves both the degeneration of
articular cartilage as well as changes to the subchondral
bone2, however, the pathophysiology behind the structural
changes associated with the disease is complex and poorly
understood.
Currently, there are no commercially available drugs
definitively proven to alter the natural progression of this
disease in the clinic. The supplements, glucosamine and
chondroitin sulfate, however, may have the ability to pro-
vide chondroprotective effects and improve some of the
signs and symptoms associated with OA3,4. In the absence
of disease modifying drugs, the treatment of patients with
OA is often directed at relieving pain and restoring function
through the use of pharmacologic therapies5–7. Acetami-
nophen and nonsteroidal anti-inflammatory drugs (NSAIDs)
are widely prescribed for the treatment of OA pain. The
long-term use of these agents, however, may be ac-
companied by a number of undesirable effects including
suppression of platelet aggregation and disruption of the
gastrointestinal mucosa, the latter effect frequently leading
to upper gastrointestinal erosions and ulceration8. Intra-
articular injections of corticosteroids have been demon-
strated to relieve inflammation and associated pain, but
their effect is of short duration and is therefore employed
infrequently5. For these reasons, it is apparent that the
need exists for new therapeutic agents with the ability to
attenuate OA-associated pain.
Studies designed to identify novel inhibitors of pain
associated with OA have been hampered by the lack of a
rapid, reproducible animal model that closely mimics both
the pain and structural changes associated with the dis-
ease. Both surgical and spontaneous animal models of OA
often require extended periods of time (months) to present
with the classical features of OA including pain and
changes in joint morphology9. An animal model, therefore,
that replicates the behavioral, biochemical and pharmaco-
logical parameters of OA-associated joint discomfort would
be of great value.
Injection of the metabolic inhibitor, monosodium iodo-
acetate (MIA; iodoacetic acid), into joints inhibits
glyceraldehye-3-phosphate dehydrogenase activity in
chondrocytes, resulting in disruption of glycolysis and
eventual cell death10,11. The progressive loss of
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chondrocytes results in histologic and morphologic
changes to the articular cartilage, closely resembling those
seen in human OA12. In addition, the model has been
utilized by a number of investigators to test pharmacologic
agents for their ability to preserve cartilage structure12–14.
In the present study, a rapid, reproducible rodent model
of OA joint discomfort is described. Injection of MIA into the
femorotibial joint of a rat resulted in a significant increase in
change in hind paw weight distribution, used as an index of
joint discomfort. Associated with the changes in weight
distribution were histologic changes consistent with those
noted in human OA, including loss of viable chondrocytes,
loss of proteoglycan, and cartilage fibrillation. In addition,
three commonly utilized therapies for OA pain, naproxen,
acetaminophen, and the COX2 specific inhibitor, rofecoxib,
significantly decreased changes in weight distribution in a
dose-dependent fashion. It is concluded that the rat MIA
model is a rapid, technically straightforward model that
closely mimics the behavioral, pathologic and pharmaco-
logic features associated with human OA.
Methods
INDUCTION OF OSTEOARTHRITIS
The procedures used in this study were in accordance
with the guidelines of the Pfizer Animal Care and Use
Committee. Male Wistar rats (175–200 g; Charles River,
Wilmington, MA) were housed in solid bottom cages with
corncob bedding. Animals were fed standard rat chow with
water available ad libitum. For induction of MIA-induced
arthritis, rats were anesthetized with isoflurane (Abbott
Laboratories, North Chicago, IL) and given a single intra-
articular injection of 0.1, 0.3, 1, or 3 mg MIA (Sigma,
St. Louis, MO; cat #I2512) through the infrapatellar ligament
of the right knee15,16. MIA was dissolved in physiologic
saline and administered in a volume of 50 µl using a 26
gauge, 0.5 inch needle. A Hamilton PB 600-1 repeating
dispenser with a 700 series luer tip microliter syringe
(model 750; Hamilton Company, Reno, NV) was used for
precise injection of an automated volume. The left contra-
lateral control knee was injected with 50 µl of physiologic
saline. Basal readings were established using a group of
sham rats that were injected with saline in both knees.
ASSESSMENT OF CHANGE IN HIND PAW WEIGHT DISTRIBUTION
Changes in hind paw weight distribution between the
right (osteoarthritic) and left (contralateral control) limbs
were utilized as an index of joint discomfort in the osteo-
arthritic knee. An incapacitance tester (Linton Instrumenta-
tion, Norfolk, UK) was employed for determination of hind
paw weight distribution. Rats were placed in an angled
plexiglass chamber positioned so that each hind paw
rested on a separate force plate (Fig. 1). The force exerted
by each hind limb (measured in grams) is averaged over a
5-s period. Each data point is the mean of three, 5-s
readings. The change in hind paw weight distribution was
calculated by determining the difference in the amount
of weight (g) between the left and right limbs. Results
are presented as either the difference in weight bearing
between the left (contralateral control) limb and right
(osteoarthritic) limb or as the percent difference between
baseline reading and post-treatment as calculated by the
following equation:
(1(mean  weight of treated group/
mean  weight of vehicle group))(100)
Fig. 1. Incapacitance tester: rats are placed in an angled plexiglass chamber and are allowed to acclimate for a period of 5–10 min before
any readings are taken. When the rat is in the proper position (both hind paws on their respective force plates, both front paws on the
plexiglass ramp, and facing forward) three, 5-s readings are recorded.
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HISTOLOGIC ANALYSIS
Histologic changes were assessed in rats that had re-
ceived 1 mg of MIA. Rats were euthanized by CO2 at the
time indicated. Soft tissue was removed from the right
(osteoarthritic) and left (contralateral control) legs. The
patella was removed from each knee to facilitate thorough
fixation of the joint. Tissue samples were prepared for light
microscopy using standard procedures. Briefly, samples
were preserved in 10% neutral-buffered formalin (VWR,
So. Plainfield, NJ), and subsequently decalcified in 5%
formic acid for 72 h. Samples were dehydrated in an
ethanol series and embedded in paraffin. Sections were
stained with either hematoxylin–eosin or toluidine blue
according to previously published methods17.
To assess the degree of synovial inflammation a relative
scoring system was used. Each joint was scored on a scale
of 0–4 as follows: 0=no inflammation, 1=minimal, 2=mild,
3=moderate, and 4=marked. Inflammation was character-
ized by expansion of the synovial membrane by protein-
aceous edema fluid and fibrin with infiltrating macrophages,
neutrophils, plasma cells and lymphocytes. All samples were
scored by a Board-certified veterinary pathologist (RG).
COMPOUND ADMINISTRATION
Naproxen (sodium salt; Sigma–Aldrich; St. Louis, MO)
was dissolved in hydroxypropylmethylcellulose (HPMC)
vehicle (0.5% HPMC+0.2% Tween 80). Rofecoxib (Merk
and Co., Inc., Whitehouse Station, NJ) and acetaminophen
tablets (Tylenol; paracetamol; McNeil Consumer and
Speciality Pharmaceuticals, Fort Washington, PA) were
pulverized and suspended in HPMC vehicle. A separate
vehicle group in which rats were dosed with HPMC
alone was run in conjunction with the drug-treated groups.
Fourteen days post-MIA injection, changes in hind paw
weight distribution were determined, as described pre-
viously, to establish a baseline pain reading. The rats (N8
per group) were then given a single dose (oral gavage) of
vehicle, naproxen, acetaminophen or rofecoxib at 0.1, 1.0,
10, or 100 mg/kg. Changes in hind paw weight distri-
bution were determined 2, 4 and 6 h post-compound
administration.
STATISTICAL ANALYSIS
All data are expressed as mean±S.E.M. All statistical tests
were tested at the 0.05 level of statistical significance. A
standard dose response (Hill) model18 was fit to estimate
the EC50 of MIA for the change in hind paw weight
distribution dose response. Each mean response for a
concentration of MIA was compared to the mean saline
response by Dunnett’s test19.
For studies examining naproxen and rofecoxib, median
percent inhibitions in hind paw weight distribution for each
of the doses were compared with zero percent inhibition via
the Wilcoxon signed-rank test20 adjusted for multiplicity of
statistical testing with Hochberg’s procedure.
Changes in hind paw weight distribution over hours 2, 4,
and 6 were adjusted for pre-dose (baseline) levels and
modeled as a function of treatment, time and the combined
effect of treatment and time (treatment by time interaction)
with a repeated measures analysis. The mean changes in
hind paw weight distribution over time for the treatment
groups were compared with the mean change in hind paw
weight distribution over time in the vehicle controls via the
Dunnett–Hsu multiple comparisons procedure21.
Results
MIA-INDUCED JOINT DISCOMFORT
Injection of MIA into the right knee resulted in a
concentration- and time-dependent increase in joint dis-
comfort as defined by change in hind paw weight distri-
bution (Figs. 2 and 3). All doses of MIA significantly (N8
rats per group; representative of two separate experiments;
P<0.05) increased the change in hind paw weight distri-
bution 14 days post-injection as compared to sham-
injected rats (saline in both knees; Fig. 2). The maximal
degree of weight shift was noted using a concentration of
1 mg/joint. The EC50 was determined to be 0.54 mg using
the Hill model of dose response. No further increase in
weight shift was noted when the concentration was in-
creased to 3 mg/joint, therefore, 1 mg/joint was selected as
the lowest maximally effective dose for further studies
involving histopathology and pharmacologic response.
The temporal pattern of MIA-induced change in weight
bearing was determined using concentrations ranging from
0.1 to 3 mg/joint (Fig. 3). The same groups of rats were
followed throughout the course of the experiment (1, 3, 7,
and 14 days post-injection). The sham (saline-injected)
hind paw weight differential was found to be 0±1 g (N6
rats; representative of three separate experiments). A bi-
phasic pattern of joint discomfort was noted in all of the MIA
concentrations tested except for the 0.1 mg/knee. The first
phase of increased change in weight bearing was achieved
at a maximal level 1 day post-MIA followed by a decrease
at day 3. By day 7 post-injection, the change in hind paw
weight distribution had again increased to the maximal
level of weight-bearing differential and remained elevated
throughout the remainder of the 14-day protocol. The
change in weight distribution noted at the 14-day time point
was not significantly different from that noted at 7 days
post-MIA injection. The degree of joint pain remained
consistent even when the duration of the protocol was
extended out to 6 weeks post-MIA (data not shown).
Changes in hind paw weight distribution were deter-
mined in normal rats vs saline and MIA-injected rats for the
purpose of demonstrating the reproducibility of the inca-
pacitance tester (Fig. 4). MIA-injected rats (1 mg; N8),
saline-injected (N6) and normal (no injection; N12) rats
were measured as described previously. After acclimating
the rats to the plexiglass box, three, 5-s readings were
taken on the incapacitance tester, designated repeat
numbers 1, 2, and 3. These three readings are normally
averaged together to obtain the final change in hind paw
weight distribution, however, in order to examine the varia-
bility between each repeat, all the three repeats were
represented on the graph as the mean of each repeat±S.E.M.
for each group of rats (MIA, saline, and normal). The
three readings were consistent for all three groups of rats
tested. In addition, the saline-injected rats did not demon-
strate a change in weight distribution and were similar to
normal rats.
MIA-INDUCED HISTOLOGIC CHANGES
The early (days 1–3) histologic changes to MIA-injected
joints (1 mg) exhibited alterations to both the surrounding
synovium and to the articular cartilage. As shown in Fig. 5A,
the degree of inflammation was maximal at day 1 followed
by a rapid decrease. By day 7, the inflammation had largely
resolved. Histologically, a robust inflammatory response
was noted 1 day following administration of MIA, which
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began to subside by 3 days post-injection [Fig. 5(B)]. When
present, the inflammation was characterized by expansion
of the synovial membrane by proteinaceous edema fluid
and fibrin with infiltrating macrophages, neutrophils,
plasma cells and lymphocytes. By day 7 and for the
remainder of the protocol, inflammation within the
synovium and surrounding tissue had largely resolved.
Figure 6A and B represents a saline-injected contralat-
eral control knee with intact, healthy cartilage and no loss of
chondrocytes or proteoglycan. By day 7 post-MIA injection
Fig. 2. MIA concentration–response relationship: effect of MIA injection into the rat knee. Rats injected with 0.1, 0.3, 1.0 or 3.0 mg of MIA in
the right (osteoarthritic) knee and saline in the left (contralateral control) knee. Change in hind paw weight distribution (weight bearing) was
assessed by use of an incapacitance tester 14 days after MIA injection. A fifth group of rats was injected with saline in both knees for
determination of baseline weight distribution. Statistically significant differences were determined by one-way ANOVA followed by Dunnett’s
multiple comparison’s test (*P<0.05) vs saline-injected rats. N8 rats (MIA-injected) or 6 rats (sham) per group. Representative of two
separate experiments.
Fig. 3. Temporal pattern of MIA-induced joint pain. Rats injected with 0.1, 0.3, 1.0 or 3.0 mg of MIA in the right knee and saline in the left knee
were assessed on an incapacitance tester 1, 3, 7, and 14 days after injection for change in hind paw weight distribution. Sham rats received
saline in both knees. Statistically significant differences were determined using the Hochberg’s procedure (*P<0.05 vs saline group).
j=3.0 mg MIA, m=1.0 mg MIA, M=0.3 mg MIA, and .=0.1 mg MIA. N8 rats (MIA-injected) or 6 rats (sham) per group. Representative of
two separate experiments.
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[Fig. 6(C and D); MIA1 mg] there was moderate collapse
of the cartilaginous matrix with complete loss of cellular
detail. It should be noted that cartilage damage primarily
affected only the medial tibial plateau.
Rats sacrificed 14 days post-injection [Fig. 6(E and F);
MIA1 mg] were found to have focally extensive areas of
full thickness cartilage damage characterized by complete
loss of cellular detail and some loss of proteoglycan matrix
as determined by toluidine blue staining. In less affected
areas, there was partial damage that extended approxi-
mately one third of the thickness of the cartilage. At the
transition zone between damaged and viable cartilage,
chondrocytes were isolated, variably sized and tightly
aggregated in clusters (chondrones). Furthermore, some
samples demonstrated visible marginal changes related to
osteophyte growth.
EFFECT OF ARCHETYPAL ANALGESICS
Experiments designed to determine the effects of arche-
typal analgesics on MIA-induced weight-bearing differential
utilized an MIA concentration of 1 mg/knee and were con-
ducted on day 14 post-MIA injection. Naproxen, rofecoxib,
and acetaminophen significantly decreased change in
hind paw weight distribution in a dose-dependent manner
(Fig. 7). Naproxen significantly decreased change in hind
paw weight distribution at a dose of 1 mg/kg. In contrast,
rofecoxib and acetaminophen required a dose of 10 mg/kg
to achieve a significant decrease in weight differential.
The duration of action between naproxen, rofecoxib, and
acetaminophen (Fig. 8) were similar. All three analgesics
significantly decreased change in hind paw weight distri-
bution for the duration of the 6-h study. No changes in
physical or behavioral effects (i.e., drowsiness or agitation)
were noted at any dose of the compounds. In addition,
compounds did not show any effect on cartilage structure
as compared to vehicle-treated rats (data not shown).
Discussion
The disease processes that lead to the structural
changes and pain associated with OA are complex and
poorly understood. Studies to elucidate the pathophysiol-
ogy of OA and identify therapeutic interventions to treat the
disease have been hampered by the lack of a rapid,
reproducible animal model that mimics both the histologic
changes and symptoms (i.e., pain) associated with the
disease. The present study describes a rat model of
OA-associated joint discomfort that allows both the rapid
analysis of the mechanisms involved with OA pain and the
evaluation of therapeutic interventions to treat the joint
discomfort associated with the disease.
This model involves the intra-articular injection of MIA
into the right femorotibial joint of Wistar rats. The MIA
model is well established and has been utilized in a number
of different species including horses, chickens, mice,
guinea pigs and rats11,22–24. Intra-articular injection of MIA
results in an inhibition of glyceraldehye-3-phosphate, ulti-
mately resulting in disruption of chondrocyte metabolism
and eventual cell death10,11. This progressive loss of
chondrocytes results in histologic changes that resemble
several of the salient features noted in human OA, includ-
ing collapse of the cartilaginous matrix, fibrillation, and
osteophyte formation. The amount of MIA utilized in this
study was chosen based on both the degree of joint
discomfort and the histologic changes. Interestingly, histo-
logic examination revealed that the MIA primarily targets
the articular cartilage of the medial tibial plateaus. This is
supported by the fact that the rat is a medial weight-bearing
animal and is also consistent with a previous study by
Williams and Brandt25 demonstrating a requirement for
weight bearing on the affected joint for lesion development.
Based on these findings, it is apparent that the model
appears to reproduce the early lesions of OA, similar to
those observed in the human disease. Due to these
Fig. 4. Evaluation of the reproducibility of the incapacitance tester to evaluate change in hind paw weight distribution. Rats injected with
either, 1 mg MIA in the right knee and saline in the left knee (MIA-injected rats; j), saline in both knees (sham rats; n), or no injection in
either knee (normal rats; *). Change in hind paw weight distribution (weight bearing) was assessed by the use of an incapacitance tester
14 days after MIA or saline injection. Each data point is one repetition, which is the mean of a single 5-s reading (representative of three
experiments). N8 rats (MIA-injected), 12 rats (normal), or 6 rats (saline-injected; sham).
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Fig. 5. Inflammation in the rat knee due to MIA-injection. A. Inflammation was assessed and scored 1, 3, 7, and 14 days post-MIA (1 mg; N4
rats per time point). B. Frontal sections of the medial aspect of rat knee joints injected with 1 mg MIA; (A) 1 day post-MIA injection, showing
significant expansion of the synovial membrane with a large amount of cellular infiltrate; (B) 3 days post-MIA injection, synovial membrane
expansion and cellular infiltrate still present to a lesser degree; (C) 7 days post-MIA injection, little to no changes present in the synovium;
(D) 14 days post-MIA injection, no presence of inflammation. The sections were stained with hematoxylin and eosin. Magnification×10.
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histologic similarities, various adaptations of the model
have been utilized to examine both the pathophysiology
of OA and a number of pharmacologic agents includ-
ing NSAIDs, corticosteroids and inhibitors of matrix
metalloproteinases10,12–14. These studies, however, have
relied on histologic/morphologic end points for determi-
nation of efficacy and do not address the ability of these
agents to modify the symptoms associated with OA. The
model outlined in the present study describes a rapid,
technically straightforward model that closely mimics
the pathologic and behavioral features associated with
human OA.
Several previous studies have demonstrated significant
changes in gait and mobility following injection of MIA16,26.
It is apparent, however, that these behavioral paradigms do
not lend themselves to the rapid analysis of a large number
of animals. In the present study, we utilized the differential
in weight bearing between the right (osteoarthritic) and left
Fig. 6. Time course of histologic changes and proteoglycan loss after injection with 1 mg MIA. Frontal sections of the medial aspect of rat
knee joints were stained with hematoxylin and eosin (A–E) or toluidine blue (B–F). (A and B) Saline-injected left knee demonstrating normal
healthy cartilage. (C and D) 7 days post-MIA injection. A lesion covers half of the medial tibial plateau and extends well into the deep zone.
Chondrocyte loss is readily apparent along with a slight loss of proteoglycan. (E and F) 14 days post-MIA injection. A significant lesion covers
two third of the medial tibial plateau. Chondrocyte loss is complete to the deep zone and significant proteoglycan loss can be detected all
the way to the tidemark. Magnification×10. Representative of a minimum of three separate experiments (N8 rats per study).
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(contralateral control) limbs as an indication of joint discom-
fort. This approach has been shown previously to be a
rapid and objective method by which to assess both arth-
ritic and bone cancer pain27,28. Administration of MIA into
the right femorotibial joint of Wistar rats resulted in a time-
and concentration-dependent increase in joint discomfort
Fig. 7. Rofecoxib, naproxen, and acetaminophen dose–response: percent inhibition of change in hind paw weight distribution. Rats were
injected with 1 mg of MIA in the right knee and saline in the left knee on day 0. On day 14, rats were assessed on an incapacitance
tester for change in hind paw weight distribution and then administered 0.1, 1, 10, or 100 mg/kg rofecoxib, naproxen, or acetaminophen
(PO). Vehicle control rats received HPMC. Two hours later, the rats were reassessed. Statistically significant differences were determined
using a Wilcoxon signed-rank test followed by a Hochberg’s multiple comparison procedure (*P<0.05). M=rofecoxib, .=naproxen, and
m=acetaminophen. N8 rats per group. Representative of a minimum of two separate experiments.
Fig. 8. Duration of effect of rofecoxib, naproxen and acetaminophen on change in hind paw weight distribution. Rats were injected with 1 mg
of MIA in the right knee and saline in the left knee on day 0. On day 14 the rats were assessed on an incapacitance tester for change in hind
paw weight distribution and then administered 10 mg/kg rofecoxib, naproxen, or acetaminophen (PO). The rats were reassessed 2, 4 and
6 h later. Statistically significant differences were determined using a repeated measures analysis. A statistically significant difference existed
between the mean change from pre-dose pain response in the control subjects and the mean change from pre-dose pain responses in the
rofecoxib, naproxen and acetaminophen groups over hours 2–6 (*P<0.05). .=vehicle, M=rofecoxib, m=naproxen, and j=acetaminophen.
N8 (vehicle and rofecoxib), 4 (naproxen), or 6 (acetaminophen) rats per group. Representative of a minimum of two separate experiments.
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(Figs. 2 and 3). When administered at 1 mg per joint,
change in weight distribution was found to reach a maximal
level within 7 days and maintained this level for up to
6 weeks (Fig. 2; 6 week data not shown). Interestingly,
the temporal changes in weight distribution noted upon
addition of MIA demonstrated a biphasic pattern as de-
scribed in the results (Fig. 3). These findings are in
accordance with those of Guingamp et al. who previously
noted a similar biphasic pattern using biotelemetric as-
sessment of the spontaneous nocturnal mobility of rats
injected with MIA16. Coincident with the first phase of
increased change in hind paw weight distribution was a
substantial inflammatory response within the affected joint
[Fig. 5(A)]. Closely tracking the first phase of increased
weight distribution was the degree of inflammation, which
was maximal at day 1 and found to decrease by day 3.
By day 7 the inflammatory response had largely resolved,
although there were areas of extensive cartilage damage
[Figs. 5(B) and 6(C and D)]. Thus, it is possible that the
first phase of the joint discomfort may have been medi-
ated by the inflammatory infiltrate within the synovium
while the second phase (days 7–14) may be due to
structural changes within the joint (i.e., alterations to the
subchondral bone as noted previously by both Janusz
et al. and Guzman et al.)12,29.
One of the primary lines of support for the validity of the
model in the setting of OA pain is provided by the ability
of acetaminophen30 and the NSAIDs naproxen5 and
rofecoxib31 to alleviate the joint discomfort following an
injection of MIA. Oral administration of acetaminophen, the
COX-1/2 inhibitor, naproxen, or the COX-2 specific inhibi-
tor, rofecoxib, decreased the change in hind paw weight
distribution dose-dependently. These compounds have
been demonstrated to provide a clinically significant de-
crease in OA-associated pain in both preclinical animal
models and in the human. It should be emphasized that the
respective doses of these compounds were not optimized
for exposure and therefore, one should be cautioned
against making a direct comparison. The ability of these
compounds to attenuate joint discomfort in this model
indicates that the joint discomfort observed after MIA injec-
tion is susceptible to pharmacologic intervention by a
commonly utilized therapeutic agent.
Several issues pertaining to the relevance of this model
to human OA warrant comment. Of importance is the
anatomical origin of the MIA-induced joint discomfort.
Based on the histologic findings, it is apparent that a
significant degree of cartilage damage is present within
7 days post-MIA. Although cartilage loss is one of the
characteristic pathologic features of clinical OA and is
noted in this model, hyaline cartilage is aneural2. It is
apparent, therefore, that other, non-cartilage-related
mechanisms are responsible for mediating pain in this
model. Other locations adjacent to the cartilage, however,
are innervated including the synovium, meniscus and
ligaments. As mentioned previously, there is a substantial
inflammatory response within the synovium early in the
pathogenesis of the model, but this has generally resolved
by 3 days post-MIA and would therefore not be expected to
play a role in mediating joint discomfort at later time points.
Recent evidence has indicated that bone marrow lesions/
edema may play a role in mediating the pain associated
with OA32 and may, therefore, represent a possible expla-
nation as to the anatomic source of pain in this model. In
addition, the contribution of neuropathic pain and other
neurologic mechanisms to the development of pain in this
model remain to be elucidated.
We conclude that the rat MIA model of OA-like joint
discomfort represents a straightforward, technologically
feasible in vivo model. The model has several advantages
to existing paradigms, including rapid throughput and a
high degree of reproducibility. The responsiveness of this
model to conventional pain-reliving therapies indicates that
it may be useful for discerning therapeutic approaches
designed to treat the joint discomfort associated with OA.
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